Table 3.

Update on patient accrual into the IDEA trial (updated at the end of February 2013)

Trial site	Trial	Group	Current (stage III)	Planned accrual
UK, Australia, Denmark, Spain, Sweden, New Zealand	SCOT	CACTUS, OCTO	3,295	4,000
Italy	TOSCA	GISCAD*	2,389	2,500
France	IDEA	GERCOR, PRODIGE (FFCD – Unicancer)	1,479	2,000
US	80702	CALGB/SWOG	972	2,500
Greece	HORG	HORG	432	1,000
Japan	ACHIEVE	JFMC	230	1,200
Total	6 trials	16 groups	8,797	≥10,500

SCOT, Short Course Oncology Treatment; TOSCA, Three or Six Colon Adjuvant; IDEA, International Duration Evaluation of Adjuvant Chemotherapy; CLEAR, Celecoxib and Length of Adjuvant Rx; HORG, Hellenic Oncology Research Group; ACHIEVE, Adjuvant Chemotherapy for colon cancer with HIgh EVidencE; CACTUS, Cancer Clinical Trials Unit Scotland; OCTO, Oncology Clinical Trials Office, APRIC, Associazione Per la RIcerca Clinica; GIRCG, Gruppo Italiano Ricerca Cancro Gastrico; *GISCAD and collaborating groups, Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente; GOAM, Gruppo Oncologico Aree Metropolitane; GOCSI, Gruppo Oncologico del Centro Sud e lsole; GOCCI, Gruppo Oncologico Chirurgico Cooperativo Italiano; GOIRC, Gruppo Oncologico Italiano di Ricerca Clinica; GOIM, Gruppo Oncologico Italia Meridionale ; GONO, Gruppo Oncologico del Nord Ovest; IOR, Istituto Oncologico Romagnolo; ITMO, Italian Trials in Medical Oncology; SICOG, Southern Italy Cooperative Oncology Group; SICOG, Southern Italy Cooperative Oncology Group; GERCOR, Groupe Coopérateur Multidisciplinaire en Oncologie; PRODIGE, Partenariat de recherche en oncologie digestive; FFCD, Fédération Francophone de Cancérologie Digestive; CALGB, Cancer and Leukemia Group B; SWOG, Southwest Oncology Group; JFMC, Japanese Foundation for Multidisciplinary Treatment of Cancer